TRANSTHERA-B (02617) has announced that on May 19, 2026, prior to the trading session, the company entered into a placement agreement with a placement agent. Under this agreement, the placement agent, acting on a best-efforts basis, will procure placees to subscribe for 3.836 million placement shares at a price of HK$40.83 per share. Assuming no change in the number of issued shares from the date of the announcement to the settlement date, the 3.836 million placement shares represent approximately 1.24% of the existing issued H shares and 0.95% of the total existing issued shares as of the announcement date. Following the completion of the placement and the issuance of the new shares, they will constitute about 1.23% of the enlarged issued H share capital and approximately 0.94% of the total enlarged issued share capital, assuming full subscription. It is expected that the placement agent will procure no fewer than six placees, who will be professional, institutional, or other investors, to subscribe for the placement shares. The placees will be determined by the placement agent in accordance with the requirements of the Listing Rules. To the best of the directors' knowledge, information, and belief, the placees and their respective ultimate beneficial owners are, or will be, independent third parties. It is not expected that any placee will become a substantial shareholder of the company immediately following the completion of the placement. The placement price of HK$40.83 per share represents a discount of approximately 18.01% compared to the closing price of HK$49.80 per H share on The Stock Exchange of Hong Kong on May 18, 2026, the last trading day. Assuming all placement shares are fully subscribed and upon completion, the gross proceeds from the placement are expected to be approximately HK$157 million, with net proceeds (after deducting placement commissions and other related costs and expenses) estimated at around HK$152 million. On this basis, the net issue price will be approximately HK$39.66 per share. Approximately 90% of the net proceeds from the placement are intended to be used for the development of new indications for the company's core product, Tinengotinib, with the remaining approximately 10% allocated for working capital and general corporate purposes.
Comments